Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Puma BiotechnologyPBYI +0.52%53 Price-to-Tangible-Book is 4.40 as of Aug. 04, 2026, which is 42% below its 10-year median of 7.62. GuruFocus rates PBYI with a GF Score™ of 53/100 and a GF Value™ of $3.34 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 1,148 Biotechnology companies, Puma Biotechnology ranks worse than 61.85% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Puma Biotechnology Price-to-Tangible-Book Related Terms
Puma Biotechnology Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Puma Biotechnology's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBYI vs EVMN, OCGN, EDIT: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Puma Biotechnology's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Puma Biotechnology Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Puma Biotechnology (PBYI) has a Price-to-Tangible-Book of 4.40 as of Aug. 04, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Puma Biotechnology and its competitors. This is 42% below median its historical median of 7.62. Over the past decade, Puma Biotechnology's Price-to-Tangible-Book has ranged from 2.93 to 38,790.00. According to the industry distribution chart, Puma Biotechnology ranks #710 out of 1148 companies in the Biotechnology industry, placing it in the top 61.8%.
Is Puma Biotechnology's Price-to-Tangible-Book too high?
Puma Biotechnology's current Price-to-Tangible-Book of 4.40 is 42% below median its 10-year median of 7.62. Over the past 10 years, this metric has ranged from a low of 2.93 to a high of 38,790.00. The Biotechnology industry median Price-to-Tangible-Book is 3.11. Puma Biotechnology's value of 4.40 is 41.7% above this industry median. Based on the distribution chart, Puma Biotechnology ranks #710 out of 1148 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's Price-to-Tangible-Book compare to EVMN and OCGN?
According to the Biotechnology industry distribution chart, Puma Biotechnology ranks #710 out of 1148 companies for Price-to-Tangible-Book. This places Puma Biotechnology in the lower half of its industry. The industry median Price-to-Tangible-Book is 3.11. Puma Biotechnology's value of 4.40 is 41.7% above this benchmark. Historically, Puma Biotechnology's own Price-to-Tangible-Book has ranged from 2.93 to 38,790.00 over the past decade. While the company's 10-year median is 7.62 vs. the industry median of 3.11, Puma Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.11, based on 1,148 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Puma Biotechnology's current Price-to-Tangible-Book of 4.40 is 41.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Puma Biotechnology and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Puma Biotechnology's current Price-to-Tangible-Book is 4.40, which is 42% below median its own 10-year median of 7.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.34, compared to a current price of $7.73 — trading 131.4% above its estimated fair value. The current Price-to-Tangible-Book is 4.40, which is 42% below median its 10-year median of 7.62 and 41.7% above the Biotechnology industry median of 3.11. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current Price-to-Tangible-Book is 4.40 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Puma Biotechnology (PBYI) Overvalued in 2026?
Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued.
The current stock price of $7.73 is trading 131.4% above its estimated GF Value™ of $3.34.
GuruFocus considers Puma Biotechnology to be Significantly Overvalued.
Key valuation signals for PBYI:
Price-to-Tangible-Book: 4.40 (42% below median its 10-year median of 7.62)
GF Value™: $3.34 vs. price of $7.73 (131.4% above fair value)
Industry Position: 41.7% above the Biotechnology median (#710 of 1148)
No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score
Get the complete analysis for PBYI
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBYI has been successfully added to your 
